Humira (Adalimumab)
adalimumab 80 mg/0.8 mL injection, 0.8 mL pen device · INJECTION · PBS code 12448E
AUTHORITY_REQUIREDWhat it costs
AU$618.9 PBS-determined price per 2 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2021-04-01.
- • Repeats: 5.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Moderate to severe hidradenitis suppurativa
First continuing treatment
Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND
Patient must have demonstrated a response to treatment with this drug for this condition; AND
Must be treated by a dermatologist.
A response to treatment is defined as:
Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) of a 50% reduction in AN count compared to baseline with no increase in abscesses or draining fistulae.
An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.
Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.
A maximum of 24 weeks treatment will be authorised under this restriction per continuing treatment.
The authority application must be made via the Online PBS Authorities System, or in writing via HPOS form upload or mail and must include:
(i) the Hidradenitis Suppurativa Clinical Response (HiSCR) result.
If the application is submitted through HPOS form upload or mail, it must include:
(i) details of the proposed prescription(s); and
(ii) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Moderate to severe hidradenitis suppurativa
Subsequent continuing treatment
Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND
Patient must have demonstrated a response to treatment with this drug for this condition; AND
Must be treated by a dermatologist.
A response to treatment is defined as:
Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) of a 50% reduction in AN count compared to baseline with no increase in abscesses or draining fistulae.
An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.
Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.
A maximum of 24 weeks treatment will be authorised under this restriction per continuing treatment.
The authority application must be made via the Online PBS Authorities System, or in writing via HPOS form upload or mail and must include:
(i) the Hidradenitis Suppurativa Clinical Response (HiSCR) result.
If the application is submitted through HPOS form upload or mail, it must include:
(i) details of the proposed prescription(s); and
(ii) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).
Sponsor: AbbVie Pty Ltd ABN 48 156 384 262
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.